Skip to main content
NAGE
NASDAQ Life Sciences

Niagen Q3 Sales Fall 20% to $27.2M; Swings to $1.2M Loss as Ingredient Demand Slips

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.52
Mkt Cap
$199.398M
52W Low
$2.31
52W High
$7.95
52W Position info
9.1% above low
Off High info
68% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

NAGE is trading near its 52-week low of $2.31 (9.1% above the low).

Summary

Niagen's Q3 revenue fell 20% to $27.2M and the company swung to a $1.2M net loss as ingredient sales dropped 47%. Cash of $69.5M and a favorable appeals ruling on the $9.2M Elysium fee award soften the blow.


Key Events · Earnings and Guidance · NAGE

  • Q3 Revenue Falls 20%

    Net sales were $27.2M versus $33.99M a year earlier; consumer products fell 10% to $23.3M and ingredients dropped 47% to $3.8M.

  • Quarter Swings to Net Loss

    Q3 net loss of $1.2M (-$0.01 per share) versus $4.6M net income a year ago, as operating expenses rose to $18.7M from $17.7M.

  • Nine-Month Profit Boosted by Divestiture

    Nine-month net income of $6.1M included a $4.8M gain on the February 2026 sale of the analytical reference standards segment; operating cash flow fell to $4.2M from $12.8M.

  • Elysium Fee Award Reversed

    On October 30, 2026 the Federal Circuit reversed the $9.2M attorneys' fee judgment; management now considers a material loss remote and no accrual is recorded.


Analysis · NAGE · Life Sciences

Revenue is shrinking faster than costs: Q3 sales dropped 20% to $27.2M while operating expenses rose to $18.7M, turning a $4.6M profit a year ago into a $1.2M loss. The ingredients segment is the weak spot, down 47% in the quarter as the largest ingredient customer cut purchases amid softer demand and NMN competition. The offset is a strong balance sheet — $69.5M of cash, no debt, and a $50M ATM that has not been drawn — so this is a growth problem, not a solvency one. Separately, the October 30 Federal Circuit ruling wiped out a $9.2M attorneys' fee judgment against the company, removing a liability that had been hanging over the stock.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NAGE was trading at $2.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.4M. The 52-week trading range was $2.31 to $7.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAGE - Latest Insights

NAGE
Nov 04, 2026, 4:02 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $2.16 info
Change: -$0.3619 (-14%) info
Market Cap: $166.56M info
NAGE
Nov 04, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $2.16 info
Change: -$0.3619 (-14%) info
Market Cap: $166.56M info
NAGE
Aug 04, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $2.16 info
Change: -$1.04 (-33%) info
Market Cap: $166.56M info
NAGE
Aug 04, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.22
Real-time Price: $2.16 info
Change: -$1.06 (-33%) info
Market Cap: $166.56M info
NAGE
Aug 04, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.22
Real-time Price: $2.16 info
Change: -$1.06 (-33%) info
Market Cap: $166.56M info